knowledge -WSS

knowledge

author：explore 2025-10-01 23:57:35 - browse：9

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

leisure time

WSS

New safety details link Apellis eye drug to rare cases of blindness

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Scientists inch closer to single

Wildfire pollution widens asthma inequities on Long Island

STAT Summit: How researchers deal with rejection

focus

knowledge

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Breakthrough Alzheimer’s drugs are inaccessible in rural states

BioMarin wins approval for gene therapy to treat hemophilia A

ADCs take center stage as promising cancer treatments

The high cost of giving birth even with insurance

Roche acquires Telavant from Roivant, adding experimental IBD treatment

In Memoriam: Notable people who died in 2023

STAT Summit: Ending the crisis of Black deaths in the U.S.

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Readout Newsletter: Biotech news today

knowledge

Vertex non

New safety details link Apellis eye drug to rare cases of blindness

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Sage hopes for a blockbuster in antidepressant now before FDA

Mega Millions pot grows to $1.25 billion after no winner

Roivant's CEO is a star, but biotech's black hole persists

focus

hotspot

leisure time

leisure time